NCT06927297View on ClinicalTrials.gov

Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2028

Conditions
Advanced Solid Tumor MalignanciesAdvanced Solid Malignancies
Interventions
BIOLOGICAL

Engineered mitochondria vaccine

Participants were assigned to receive subcutaneous injections of the low dose, medium dose, or high-dose of the engineered mitochondrial vaccine. The regimen consisted of 3 doses of primary immunization, 1 dose of boost immunization and subsequent personalized treatment.

Trial Locations (1)

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER